Is IKT or ALDX more profitable?

Inhibikase Therapeutics' return on equity of -42.80% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Inhibikase Therapeutics N/A -42.80% -40.58% Aldeyra Therapeutics N/A -53.14% -34.94%

Do analysts recommend ALDX or ACB?

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 500.24%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Aurora Cannabis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aurora Cannabis 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Aldeyra Therapeutics (ALDX) Competitors

$0.92 -0.03 (-3.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$0.91 0.00 (-0.47%)

As of 10/9/2026 07:34 PM Eastern

Compare

ALDX vs. EYPT, VNDA, IKT, AMRN, and ACB

Should you buy Aldeyra Therapeutics stock or one of its competitors? Aldeyra Therapeutics's main competitors and comparable companies include Eyepoint Pharmaceuticals (EYPT), Vanda Pharmaceuticals (VNDA), Inhibikase Therapeutics (IKT), Amarin (AMRN), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aldeyra Therapeutics compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability.

Eyepoint Pharmaceuticals currently has a consensus price target of $25.70, indicating a potential upside of 655.88%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 500.24%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Aldeyra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eyepoint Pharmaceuticals has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, meaning that its share price is 21% more volatile than the broader market.

Aldeyra Therapeutics has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$2.79M	105.14	-$231.96M	-$3.74	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Aldeyra Therapeutics' return on equity of -53.14% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Eyepoint Pharmaceuticals had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 3 mentions for Eyepoint Pharmaceuticals and 1 mentions for Aldeyra Therapeutics. Eyepoint Pharmaceuticals' average media sentiment score of 0.00 beat Aldeyra Therapeutics' score of -0.29 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Eyepoint Pharmaceuticals	Neutral
Aldeyra Therapeutics	Neutral

Summary

Eyepoint Pharmaceuticals beats Aldeyra Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Aldeyra Therapeutics (NASDAQ:ALDX) and Vanda Pharmaceuticals (NASDAQ:VNDA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

Aldeyra Therapeutics has higher earnings, but lower revenue than Vanda Pharmaceuticals. Aldeyra Therapeutics is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Vanda Pharmaceuticals	$215.72M	1.28	-$220.47M	-$4.63	N/A

Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Vanda Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Aldeyra Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 500.24%. Vanda Pharmaceuticals has a consensus target price of $13.08, indicating a potential upside of 186.29%. Given Aldeyra Therapeutics' higher possible upside, equities research analysts plainly believe Aldeyra Therapeutics is more favorable than Vanda Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vanda Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44

Aldeyra Therapeutics has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 10.7% of Vanda Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Vanda Pharmaceuticals had 7 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 1 mentions for Aldeyra Therapeutics. Vanda Pharmaceuticals' average media sentiment score of 0.35 beat Aldeyra Therapeutics' score of -0.29 indicating that Vanda Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Neutral
Vanda Pharmaceuticals	Neutral

Summary

Vanda Pharmaceuticals beats Aldeyra Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Inhibikase Therapeutics (NASDAQ:IKT) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Inhibikase Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the broader market. Comparatively, Aldeyra Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market.

In the previous week, Inhibikase Therapeutics had 1 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 2 mentions for Inhibikase Therapeutics and 1 mentions for Aldeyra Therapeutics. Inhibikase Therapeutics' average media sentiment score of 0.15 beat Aldeyra Therapeutics' score of -0.29 indicating that Inhibikase Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Inhibikase Therapeutics	Neutral
Aldeyra Therapeutics	Neutral

3.8% of Inhibikase Therapeutics shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 7.1% of Inhibikase Therapeutics shares are held by company insiders. Comparatively, 11.8% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Inhibikase Therapeutics currently has a consensus price target of $5.40, indicating a potential upside of 174.11%. Aldeyra Therapeutics has a consensus price target of $5.50, indicating a potential upside of 500.24%. Given Aldeyra Therapeutics' higher possible upside, analysts plainly believe Aldeyra Therapeutics is more favorable than Inhibikase Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inhibikase Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.00
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aldeyra Therapeutics has lower revenue, but higher earnings than Inhibikase Therapeutics. Inhibikase Therapeutics is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inhibikase Therapeutics	$260K	1,057.28	-$48.26M	-$0.43	N/A
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A

Inhibikase Therapeutics' return on equity of -42.80% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inhibikase Therapeutics	N/A	-42.80%	-40.58%
Aldeyra Therapeutics	N/A	-53.14%	-34.94%

Summary

Aldeyra Therapeutics beats Inhibikase Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Amarin?

Aldeyra Therapeutics (NASDAQ:ALDX) and Amarin (NASDAQ:AMRN) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Aldeyra Therapeutics has a beta of 1.21, indicating that its stock price is 21% more volatile than the broader market. Comparatively, Amarin has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

Aldeyra Therapeutics has higher earnings, but lower revenue than Amarin. Amarin is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Amarin	$213.65M	1.19	-$38.80M	-$0.99	N/A

Aldeyra Therapeutics has a net margin of 0.00% compared to Amarin's net margin of -14.56%. Amarin's return on equity of -0.20% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Amarin	-14.56%	-0.20%	-0.14%

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 500.24%. Amarin has a consensus target price of $13.00, suggesting a potential upside of 8.06%. Given Aldeyra Therapeutics' higher probable upside, research analysts plainly believe Aldeyra Therapeutics is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Amarin	2 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

In the previous week, Amarin had 3 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 4 mentions for Amarin and 1 mentions for Aldeyra Therapeutics. Amarin's average media sentiment score of 0.86 beat Aldeyra Therapeutics' score of -0.29 indicating that Amarin is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Neutral
Amarin	Positive

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Amarin shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by company insiders. Comparatively, 4.2% of Amarin shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Aldeyra Therapeutics beats Amarin on 9 of the 15 factors compared between the two stocks.

How does Aldeyra Therapeutics compare to Aurora Cannabis?

Aldeyra Therapeutics (NASDAQ:ALDX) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

Aldeyra Therapeutics has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-53.14%	-34.94%
Aurora Cannabis	-32.26%	4.37%	3.45%

Aldeyra Therapeutics has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, indicating that its share price is 37% less volatile than the broader market.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Aldeyra Therapeutics has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.39	N/A
Aurora Cannabis	$247.82M	1.19	-$88.13M	-$1.41	N/A

In the previous week, Aurora Cannabis had 25 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 26 mentions for Aurora Cannabis and 1 mentions for Aldeyra Therapeutics. Aurora Cannabis' average media sentiment score of 0.15 beat Aldeyra Therapeutics' score of -0.29 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Neutral
Aurora Cannabis	Neutral

Aldeyra Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 500.24%. Given Aldeyra Therapeutics' higher possible upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aurora Cannabis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aldeyra Therapeutics beats Aurora Cannabis on 8 of the 13 factors compared between the two stocks.

Get Aldeyra Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ALDX vs. The Competition

Export

Metric	Aldeyra Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$57.17M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-2.35	797.58	274.15	26.16
Price / Sales	N/A	939.82	635.98	113.06
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	1.24	10.71	11.21	6.34
Net Income	-$33.85M	$2.84B	$3.50B	$381.90M
7 Day Performance	-21.68%	-0.93%	-0.90%	-1.41%
1 Month Performance	-37.24%	-4.91%	-4.44%	-3.48%
1 Year Performance	-83.00%	-4.13%	6.96%	1.16%

Aldeyra Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ALDX Aldeyra Therapeutics	2.5519 of 5 stars	$0.92 -3.3%	$5.50 +500.2%	-83.8%	$57.17M	N/A	N/A	6
EYPT Eyepoint Pharmaceuticals	2.4243 of 5 stars	$3.15 -3.1%	$25.70 +715.9%	-75.7%	$280.19M	$31.37M	N/A	214
VNDA Vanda Pharmaceuticals	3.7302 of 5 stars	$4.58 -1.1%	$13.08 +185.7%	-16.1%	$279.94M	$216.10M	N/A	533	News Coverage Analyst Downgrade
IKT Inhibikase Therapeutics	1.9956 of 5 stars	$2.00 flat	$5.40 +170.0%	+18.7%	$279.07M	$260K	N/A	35
AMRN Amarin	1.5742 of 5 stars	$12.09 -2.1%	$13.00 +7.5%	-36.9%	$260.87M	$213.65M	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ALDX) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. EYPT, VNDA, IKT, AMRN, and ACB

How does Aldeyra Therapeutics compare to Eyepoint Pharmaceuticals?

Summary

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Summary

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Summary

How does Aldeyra Therapeutics compare to Amarin?

Summary

How does Aldeyra Therapeutics compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aldeyra Therapeutics (ALDX) Competitors

ALDX vs. EYPT, VNDA, IKT, AMRN, and ACB

How does Aldeyra Therapeutics compare to Eyepoint Pharmaceuticals?

Do analysts rate EYPT or ALDX?

Which has more volatility & risk, EYPT or ALDX?

Which has higher valuation & earnings, EYPT or ALDX?

Is EYPT or ALDX more profitable?

Do insiders & institutionals believe in EYPT or ALDX?

Does the media prefer EYPT or ALDX?

Summary

How does Aldeyra Therapeutics compare to Vanda Pharmaceuticals?

Which has preferable earnings and valuation, ALDX or VNDA?

Which has more volatility and risk, ALDX or VNDA?

Do analysts rate ALDX or VNDA?

Is ALDX or VNDA more profitable?

Do institutionals and insiders believe in ALDX or VNDA?

Does the media prefer ALDX or VNDA?

Summary

How does Aldeyra Therapeutics compare to Inhibikase Therapeutics?

Which has more risk and volatility, IKT or ALDX?

Does the media prefer IKT or ALDX?

Do institutionals & insiders believe in IKT or ALDX?

Do analysts prefer IKT or ALDX?

Which has stronger valuation & earnings, IKT or ALDX?

Is IKT or ALDX more profitable?

Summary

How does Aldeyra Therapeutics compare to Amarin?

Which has more risk and volatility, ALDX or AMRN?

Which has higher earnings & valuation, ALDX or AMRN?

Is ALDX or AMRN more profitable?

Do analysts recommend ALDX or AMRN?

Does the media favor ALDX or AMRN?

Do insiders & institutionals believe in ALDX or AMRN?

Summary

How does Aldeyra Therapeutics compare to Aurora Cannabis?

Is ALDX or ACB more profitable?

Which has more volatility and risk, ALDX or ACB?

Do insiders and institutionals have more ownership in ALDX or ACB?

Which has preferable earnings and valuation, ALDX or ACB?

Does the media favor ALDX or ACB?

Do analysts recommend ALDX or ACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALDX vs. The Competition

Aldeyra Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools